Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
31
GALT Quote, Financials, Valuation and Earnings
Last price:
$4.24
Seasonality move
:
25.89%
Day range:
$4.02 - $4.20
52-week range:
$1.07 - $7.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
325.6K
Avg. volume:
634.9K
1-year change:
222.48%
Market cap:
$268.2M
Revenue:
--
EPS (TTM):
-$0.59
Analysts' Opinion
-
Consensus RatingGalectin Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.00, Galectin Therapeutics, Inc. has an estimated upside of 164.42% from its current price of $4.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $4.16.
Fair Value
-
According to the consensus of 1 analyst, Galectin Therapeutics, Inc. has 164.42% upside to fair value with a price target of $11.00 per share.
GALT vs. S&P 500
-
Over the past 5 trading days, Galectin Therapeutics, Inc. has overperformed the S&P 500 by 5.55% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Galectin Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Galectin Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Galectin Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Galectin Therapeutics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Galectin Therapeutics, Inc. reported earnings per share of -$0.13.
Enterprise value:
381.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-12.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$22K
Return On Assets:
-220.83%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
-1425.85%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$48K | -$36K | -$22K | -$9K | -- | |
| Operating Income | -$39.1M | -$39.6M | -$29.1M | -$9.1M | -$4.2M | |
| EBITDA | -$39.1M | -$39.5M | -$29.1M | -$9.1M | -$4.2M | |
| Diluted EPS | -$0.76 | -$0.73 | -$0.59 | -$0.18 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $38M | $17.1M | $21.6M | $28.7M | $12.7M | |
| Total Assets | $38M | $17.9M | $22.2M | $29M | $12.9M | |
| Current Liabilities | $8.3M | $9.6M | $10.5M | $25.3M | $136.4M | |
| Total Liabilities | $28.8M | $40.2M | $73M | $121.5M | $136.4M | |
| Total Equity | $9.2M | -$22.3M | -$50.9M | -$92.5M | -$123.6M | |
| Total Debt | $19.3M | $29.7M | $61.1M | $104.6M | $32.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.5M | -$33.7M | -$30.6M | -$8.5M | -$3.5M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $40M | $40.4M | $15.1M | $10M | $1.3M | |
| Free Cash Flow | -$35.5M | -$33.7M | -$30.6M | -$8.5M | -$3.5M | |
GALT
Sector
Market Cap
$268.2M
$28.1M
Price % of 52-Week High
58.35%
50%
Dividend Yield
0%
0%
Shareholder Yield
-3.61%
-1.54%
1-Year Price Total Return
222.48%
-17.67%
Beta (5-Year)
1.031
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.37
200-day SMA
Buy
Level
$3.42
Bollinger Bands (100)
Sell
Level
4.2 - 5.7
Chaikin Money Flow
Sell
Level
-2.4M
20-day SMA
Sell
Level
$5.34
Relative Strength Index (RSI14)
Sell
Level
36.45
ADX Line
Sell
Level
25.8
Williams %R
Buy
Level
-82.5
50-day SMA
Sell
Level
$5.43
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Sell
Level
-1.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-40.9678)
Sell
CA Score
(Annual)
Level (-27.543)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (48.0164)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Stock Forecast FAQ
In the current month, GALT has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GALT average analyst price target in the past 3 months is $11.00.
-
Where Will Galectin Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Galectin Therapeutics, Inc. share price will rise to $11.00 per share over the next 12 months.
-
What Do Analysts Say About Galectin Therapeutics, Inc.?
Analysts are divided on their view about Galectin Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Galectin Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Galectin Therapeutics, Inc.'s Price Target?
The price target for Galectin Therapeutics, Inc. over the next 1-year time period is forecast to be $11.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GALT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Galectin Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of GALT?
You can purchase shares of Galectin Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Galectin Therapeutics, Inc. shares.
-
What Is The Galectin Therapeutics, Inc. Share Price Today?
Galectin Therapeutics, Inc. was last trading at $4.24 per share. This represents the most recent stock quote for Galectin Therapeutics, Inc.. Yesterday, Galectin Therapeutics, Inc. closed at $4.16 per share.
-
How To Buy Galectin Therapeutics, Inc. Stock Online?
In order to purchase Galectin Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GALT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GALT
Sector
P/E ratio
--
23.88x
PEG ratio
--
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
--
1.59x
Growth Metrics
GALT
Sector
Revenue growth
--
4.73%
Earnings growth
28.99%
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.18
Profitability
GALT
Sector
Profitability FY 2024
-$37K
$3.6M
Return on invested capital
-1425.85%
-31.77%
Return on assets
-220.83%
-28.18%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
May
15
Next Earnings Date
Jan
2
Estimated Next Earnings Date
Apr
3
Balance Sheet
GALT
Sector
Total cash
$11.5M
$26.3M
Short term investments
--
$26M
Total assets
$17.5M
$76.9M
Long term debt
$32.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.12% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.13% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 7.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
